The GABAergic control of prolactin release is not affected by insulin-dependent diabetes mellitus: evidence from studies with sodium valproate.
In order to evaluate the influence of the GABAergic system in the regulation of PRL secretion in patients with IDDM, serum PRL levels were measured in 7 diabetics and in 7 normal men with sodium valproate (400 mg per os), a drug capable of increasing cerebral GABA concentrations. A significant decrease of serum PRL concentrations was observed between 30 and 120 min after sodium valproate administration in both control and diabetic subjects. The time course and magnitude of the sodium valproate effect were similar in all subjects. These data confirm the inhibitory control of the GABAergic system on PRL secretion in man as evidenced by the GABAergic drug sodium valproate. It is suggested that this system is not altered in diabetic patients.
D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism*; D006801:Humans; D008297:Male; D011388:Prolactin / Q000378:metabolism*; D011963:Receptors, GABA-A / Q000187:drug effects / Q000502:physiology*; D014635:Valproic Acid / Q000494:pharmacology*
D011963:Receptors, GABA-A; D014635:Valproic Acid; D011388:Prolactin